Variables in predicting survival based on treating "PSA-only" relapse.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Urologic oncology

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1078-1439(03)00103-0PMID 12954500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.

  2004cited by this paper
• Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

  2004cited by this paper
• Cancer Statistics, 2003

  2003cited by this paper
• Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.

  2003cited by this paper
• Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.

  2003cited by this paper
• Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.

  2003cited by this paper
• Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.

  2003cited by this paper
• Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.

  2002cited by this paper
• Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

  2002cited by this paper
• Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

  2002cited by this paper
• Prostate biopsy quantitative histology as a staging and prognostic factor.

  2002cited by this paper
• Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer.

  2002cited by this paper
• Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

  2001cited by this paper
• Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications.

  2001cited by this paper
• A catalog of prostate cancer nomograms.

  2001cited by this paper
• Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

  2001cited by this paper
• Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow‐up

  2001cited by this paper
• Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

  2001cited by this paper
• Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

  2001cited by this paper
• Combined androgen blockade in prostate cancer: meta‐analyses and associated issues

  2001cited by this paper
• The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients.

  2000cited by this paper
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

  2000cited by this paper
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.

  2000cited by this paper
• Treatment options after failure of local curative treatments in prostate cancer: a controversial issue

  2000cited by this paper
• Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.

  2000cited by this paper
• The effect on sexual interest of `Casodex' (bicalutamide). 150 mg compared with castration in patients with advanced prostate cancer

  2000cited by this paper
• Prostate specific antigen only progression of prostate cancer.

  2000cited by this paper
• Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

  2000cited by this paper
• Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers.

  2000cited by this paper
• Update of clinical and basic science research on prostate cancer from the department of defense center for prostate disease research (DOD-CPDR)

  1999cited by this paper
• Natural history of progression after PSA elevation following radical prostatectomy.

  1999influential reference
• Salvage brachytherapy for localized prostate cancer after radiotherapy failure.

  1999cited by this paper
• Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

  1999cited by this paper
• The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources.

  1999cited by this paper
• Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage.

  1999cited by this paper
• Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide

  1999cited by this paper
• Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.

  1999cited by this paper
• Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy.

  1999cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  1999cited by this paper
• Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results.

  1999cited by this paper
• Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy.

  1999cited by this paper
• Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists.

  1999cited by this paper
• Endocrine treatment of prostate cancer — recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side‐effects

  1999cited by this paper
• Management of prostate cancer after prostatectomy: treating the patient, not the PSA.

  1999cited by this paper
• Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.

  1999cited by this paper
• Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

  1999cited by this paper
• Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

  1999influential reference
• ANDROGEN DEPRIVATION THERAPY USING FINASTERIDE AND LOW DOSE FLUTAMIDE TO TREAT PSA FAILURE FOLLOWING THERAPY FOR CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE (CaP)

  1999cited by this paper
• IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY: A RANDOMIZED PHASE III EASTERN COOPERATIVE ONCOLOGY GROUP/INTER GROUP TRIAL

  1999cited by this paper
• Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.

  1998cited by this paper
• ProstaScint® scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients

  1998influential reference
• Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.

  1998cited by this paper
• Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein.

  1998cited by this paper
• A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer

  1998cited by this paper
• Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer.

  1998cited by this paper
• (111) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY

  1998cited by this paper
• Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy.

  1998influential reference
• 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.

  1998cited by this paper
• Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma

  1998cited by this paper
• Antiandrogens as Monotherapy for Prostate Cancer

  1998cited by this paper
• Treatment Options for Prostate Cancer: Part 1--Stage, Grade, PSA, and Changes in the 1990's

  1998cited by this paper
• Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy.

  1998cited by this paper
• ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.

  1998cited by this paper
• Therapeutic radiation in patients with a rising post-prostatectomy PSA level.

  1998cited by this paper
• Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide

  1998cited by this paper
• A five‐alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats

  1998cited by this paper
• Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.

  1998cited by this paper
• Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.

  1998influential reference
• Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

  1998cited by this paper
• Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.

  1998cited by this paper
• Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.

  1997cited by this paper
• Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level.

  1997cited by this paper
• Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.

  1997cited by this paper
• MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.

  1997cited by this paper
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

  1997cited by this paper
• Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.

  1997cited by this paper
• Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.

  1997influential reference
• THERAPEUTIC IRRADIATION FOR PATIENTS WITH AN ELEVATED POST-PROSTATECTOMY PROSTATE SPECIFIC ANTIGEN LEVEL

  1997influential reference
• Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.

  1997cited by this paper
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

  1997cited by this paper
• Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.

  1997cited by this paper
• Finasteride plus flutamide for prostatic carcinoma.

  1997cited by this paper
• Consensus statement: Guidelines for PSA following radiation therapy

  1997cited by this paper
• Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.

  1997cited by this paper
• The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy.

  1996cited by this paper
• Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy: A long term follow‐up

  1996cited by this paper
• Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.

  1996cited by this paper
• Combined finasteride and flutamide therapy in men with advanced prostate cancer.

  1996influential reference
• Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy.

  1996cited by this paper
• Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up.

  1996cited by this paper
• A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.

  1996cited by this paper
• Estrogens in the treatment of prostate cancer.

  1995cited by this paper
• The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.

  1995cited by this paper
• Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.

  1995cited by this paper
• Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay.

  1995cited by this paper
• Treatment with finasteride following radical prostatectomy for prostate cancer.

  1995cited by this paper
• Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

  1994cited by this paper
• Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

  1994cited by this paper
• Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

  1994cited by this paper
• Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

  1994cited by this paper

• Is Low-risk Prostate Cancer Really Low-risk? Consider Factors Affecting Biochemical Recurrence and Tumour Upgrade.

  2023cites this paper
• Prostate cancer trajectory-map: clinical decision support system for prognosis management of radical prostatectomy

  2020cites this paper
• Spine metastasis in patients with prostate cancer: Survival prognosis assessment

  2020cites this paper
• Concentration-Dependent Effects of Zinc Sulfate on DU-145 Human Prostate Cancer Cell Line: Oxidative, Apoptotic, Inflammatory, and Morphological Analyzes

  2019cites this paper
• Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels

  2016cites this paper
• Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study

  2014cites this paper
• The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer

  2013cites this paper
• Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy.

  2013cites this paper
• Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy.

  2013cites this paper
• Antiproliferative effects of zinc-citrate compound on hormone refractory prostate cancer

  2012cites this paper
• Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial

  2012cites this paper
• Potential surrogate endpoints in cancer research – some considerations and examples

  2011cites this paper
• Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

  2010cites this paper
• Why are pretreatment prostate‐specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

  2009cites this paper
• Prognostic factors of persistently detectable PSA after radical prostatectomy

  2009cites this paper
• Hormonal treatment for progression.

  2009cites this paper
• The top 13: what family physicians should know about prostate cancer.

  2008cites this paper
• The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery

  2008cites this paper
• Management of prostate cancer in the older man.

  2008cites this paper
• Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation

  2007influential citation
• [Current state of high intensity focused ultrasound (HIFU) as treatment of prostatic carcinoma].

  2007cites this paper
• Diagnostik und Therapie des PSA-Progresses nach lokaler Primärtherapie des Prostatakarzinoms

  2007cites this paper
• Complexed prostate‐specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy

  2007cites this paper
• Expression signatures that correlated with Gleason score and relapse in prostate cancer.

  2007cites this paper
• Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.

  2007cites this paper
• Original article Survival benefit for early hormone ablation in biochemically recurrent prostate cancer

  2007cites this paper
• Estado actual del ultrasonido de alta frecuencia (HIFU) en el tratamiento del adenocarcinoma prostático

  2007cites this paper
• Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

  2007cites this paper
• Endorectal MR imaging before salvage prostatectomy: tumor localization and staging.

  2006cites this paper
• Das Lokalrezidiv des Prostatakarzinoms: Hormontherapie

  2006influential citation
• Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.

  2006cites this paper
• Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer

  2006cites this paper
• [Local recurrence of prostate cancer: hormone therapy].

  2006cites this paper
• Biochemical recurrence after localized treatment.

  2006cites this paper
• [Scientific evidence on the use of high-intensity focal ultrasound (HIFU) in the treatment of prostatic carcinoma].

  2005cites this paper
• History of Diabetes, Clinical Features of Prostate Cancer, and Prostate Cancer Recurrence-Data from CaPSURETM (United States)

  2005cites this paper
• The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.

  2005cites this paper
• Circulating tumor cells predict survival in patients with metastatic prostate cancer.

  2005cites this paper
• Recidiva local después de la prostatectomía radical y radioterapia de rescate

  2005cites this paper
• Evidencia Científica actual sobre la utilidad del Ultrasonido de Alta Intensidad (HIFU) en el tratamiento del Adenocarcinoma Prostático

  2005cites this paper
• [Prostate cancer recurrence after radical prostatectomy and salvage radiotherapy].

  2004cites this paper
• PSA relapse prostate cancer: the importance of tailored therapy.

  2004cites this paper
• An analysis of risk factors for biochemical progression in patients with seminal vesicle invasion: validation of Kattan's nomogram in a pathological subgroup

  2004cites this paper
• American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

  2004cites this paper
• Natural history of disease progression in patients who fail to achieve an undetectable prostate‐specific antigen level after undergoing radical prostatectomy

  2004cites this paper
• Recidiva del cáncer de próstata después de la prostatectomía radical y radioterapia de rescate

  2004cites this paper
• Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL‐1), CD44v6 and microvessel density for prostate cancer

  2004cites this paper
• Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.

  2003cites this paper